{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:26:37Z","timestamp":1787498797220,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010041","name":"Tianjin Science and Technology Committee","doi-asserted-by":"publisher","award":["2020ZC20182"],"award-info":[{"award-number":["2020ZC20182"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40268-023-00417-7","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T06:25:19Z","timestamp":1680503119000},"page":"109-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still\u2019s Disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Ziyi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"417_CR1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol. 2018;14:603\u201318.","journal-title":"Nat Rev Rheumatol"},{"key":"417_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-021-02708-3","volume":"24","author":"T Sugiyama","year":"2022","unstructured":"Sugiyama T, Furuta S, Hiraguri M, Ikeda K, Inaba Y, Kagami SI, et al. Latent class analysis of 216 patients with adult-onset Still\u2019s disease. Arthritis Res Ther. 2022;24:7.","journal-title":"Arthritis Res Ther"},{"key":"417_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/095952879708000106","volume":"80","author":"GF Still","year":"1897","unstructured":"Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60.9.","journal-title":"Med Chir Trans."},{"key":"417_CR4","first-page":"818","volume":"33","author":"MA Balci","year":"2015","unstructured":"Balci MA, Pamuk \u00d6N, Pamuk GE, Uzundere FK, Donmez S. Epidemiology and outcome of adult-onset Still\u2019s disease in Northwestern Thrace region in Turkey. Clin Exp Rheumatol. 2015;33:818\u201323.","journal-title":"Clin Exp Rheumatol"},{"key":"417_CR5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2188\/jea.7.221","volume":"7","author":"K Wakai","year":"1997","unstructured":"Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated prevalence and incidence of adult Still\u2019s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol. 1997;7:221\u20135.","journal-title":"J Epidemiol"},{"key":"417_CR6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, S\u00e8ve P. Adult-onset Still\u2019s disease. Autoimmun Rev. 2014;13:708\u201322.","journal-title":"Autoimmun Rev"},{"key":"417_CR7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/14397595.2014.974881","volume":"25","author":"YF Asanuma","year":"2015","unstructured":"Asanuma YF, Mimura T, Tsuboi H, Noma H, Miyoshi F, Yamamoto K, et al. Nationwide epidemiological survey of 169 patients with adult Still\u2019s disease in Japan. Mod Rheumatol. 2015;25:393\u2013400.","journal-title":"Mod Rheumatol"},{"key":"417_CR8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2019.04.004","volume":"49","author":"BY Mehta","year":"2019","unstructured":"Mehta BY, Ibrahim S, Briggs W, Efthimiou P. Racial\/Ethnic variations in morbidity and mortality in adult onset still\u2019s disease: an analysis of national dataset. Semin Arthritis Rheum. 2019;49:469\u201373.","journal-title":"Semin Arthritis Rheum"},{"key":"417_CR9","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","volume":"62","author":"S Franchini","year":"2010","unstructured":"Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease. Arthritis Rheum. 2010;62:2530\u20135.","journal-title":"Arthritis Rheum"},{"key":"417_CR10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.berh.2016.08.003","volume":"30","author":"S Casta\u00f1eda","year":"2016","unstructured":"Casta\u00f1eda S, Blanco R, Gonz\u00e1lez-Gay MA. Adult-onset Still\u2019s disease: advances in the treatment. Best Pract Res Clin Rheumatol. 2016;30:222\u201338.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"417_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ncprheum0681","volume":"4","author":"LD Church","year":"2008","unstructured":"Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34\u201342.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"417_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","volume":"61","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, S\u00e8ve P. Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53\u201362.","journal-title":"Immunol Res"},{"key":"417_CR13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","volume":"85","author":"S Mitrovic","year":"2018","unstructured":"Mitrovic S, Fautrel B. New markers for adult-onset still\u2019s disease. Joint Bone Spine. 2018;85:285\u201393.","journal-title":"Joint Bone Spine"},{"key":"417_CR14","first-page":"1","volume":"00","author":"L Gillard","year":"2022","unstructured":"Gillard L, Pouchot J, Cohen-Aubart F, Kon\u00e9-Paut I, Mouterde G, Michaud M, et al. JAK inhibitors in difficult-to-treat adult-onset Still\u2019s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology. 2022;00:1\u201312.","journal-title":"Rheumatology"},{"key":"417_CR15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001246","volume":"6","author":"M Kacar","year":"2020","unstructured":"Kacar M, Fitton J, Gough AK, Buch MH, McGonagle DG, Savic S. Mixed results with baricitinib in biological-resistant adult-onset Still\u2019s disease and undifferentiated systemic autoinflammatory disease. RMD Open. 2020;6: e001246.","journal-title":"RMD Open"},{"key":"417_CR16","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19:424\u201330.","journal-title":"J Rheumatol"},{"key":"417_CR17","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"AA Fitzgerald","year":"2005","unstructured":"Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum. 2005;52:1794\u2013803.","journal-title":"Arthritis Rheum"},{"key":"417_CR18","doi-asserted-by":"crossref","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","volume":"7","author":"T Li","year":"2017","unstructured":"Li T, Gu L, Wang X, Guo L, Shi H, Yang C, et al. A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease. Sci Rep. 2017;7:13477.","journal-title":"Sci Rep"},{"key":"417_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","volume":"21","author":"F Vercruysse","year":"2019","unstructured":"Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, et al. Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther. 2019;21:53.","journal-title":"Arthritis Res Ther"},{"key":"417_CR20","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","volume":"37","author":"M Rau","year":"2010","unstructured":"Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N. Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis. J Rheumatol. 2010;37:2369\u201376.","journal-title":"J Rheumatol"},{"key":"417_CR21","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1742-1241.2007.01393.x","volume":"63","author":"Y Cagatay","year":"2009","unstructured":"Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, et al. Adult-onset still\u2019s disease. Int J Clin Pract. 2009;63:1050\u20135.","journal-title":"Int J Clin Pract"},{"key":"417_CR22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0002-9343(99)80318-0","volume":"98","author":"JS Sampalis","year":"1995","unstructured":"Sampalis JS, Esdaile JM, Medsger TA Jr, Partridge AJ, Yeadon C, Sen\u00e9cal JL, et al. A controlled study of the long-term prognosis of adult Still\u2019s disease. Am J Med. 1995;98:384\u20138.","journal-title":"Am J Med"},{"key":"417_CR23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.semarthrit.2021.06.004","volume":"51","author":"P Efthimiou","year":"2021","unstructured":"Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset still\u2019s disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum. 2021;51:858\u201374.","journal-title":"Semin Arthritis Rheum"},{"key":"417_CR24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865\u201375.","journal-title":"Ann Rheum Dis"},{"key":"417_CR25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.650295","volume":"12","author":"E Huarte","year":"2021","unstructured":"Huarte E, Peel MT, Verbist K, Fay BL, Bassett R, Albeituni S, et al. Ruxolitinib, a JAK1\/2 Inhibitor, Ameliorates cytokine storm in experimental models of hyperinflammation syndrome. Front Pharmacol. 2021;12: 650295.","journal-title":"Front Pharmacol"},{"key":"417_CR26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S. Use of the JAK Inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12: 614704.","journal-title":"Front Immunol"},{"key":"417_CR27","first-page":"1139","volume":"14","author":"A Ohta","year":"1987","unstructured":"Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still\u2019s disease: review of 228 cases from the literature. J Rheumatol. 1987;14:1139\u201346.","journal-title":"J Rheumatol"},{"key":"417_CR28","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/rheumatology\/keaa576","volume":"60","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Xie L, Jia B, Taylor PC, Burmester G, Tanaka Y, et al. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study. Rheumatology (Oxford). 2021;60:2256\u201366.","journal-title":"Rheumatology (Oxford)"},{"key":"417_CR29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/key414","volume":"58","author":"C Ladhari","year":"2019","unstructured":"Ladhari C, Jorgensen C, Pers YM. Treatment of refractory adult onset Still\u2019s disease with combination anakinra and baricitinib therapy. Rheumatology (Oxford). 2019;58:736\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"417_CR30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","volume":"79","author":"Q Hu","year":"2020","unstructured":"Hu Q, Wang M, Jia J, Teng J, Chi H, Liu T, et al. Tofacitinib in refractory adult-onset Still\u2019s disease: 14 cases from a single centre in China. Ann Rheum Dis. 2020;79:842\u20134.","journal-title":"Ann Rheum Dis"},{"key":"417_CR31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s13104-021-05860-w","volume":"14","author":"S Yoshida","year":"2021","unstructured":"Yoshida S, Yamada S, Yokose K, Matsumoto H, Fujita Y, Asano T, et al. Interferon-\u03b3 induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. BMC Res Notes. 2021;14:447.","journal-title":"BMC Res Notes"},{"key":"417_CR32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.21084","volume":"83","author":"S Gianella","year":"2008","unstructured":"Gianella S, Schaer DJ, Schwarz U, Kurrer M, Heppner FL, Fehr J, et al. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still\u2019s disease and concurrent macrophage activation syndrome. Am J Hematol. 2008;83:424\u20137.","journal-title":"Am J Hematol"},{"key":"417_CR33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jbspin.2013.04.011","volume":"80","author":"C Banse","year":"2013","unstructured":"Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerr\u00e9 T, L\u00e9vesque H. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still\u2019s disease. Joint Bone Spine. 2013;80:653\u20135.","journal-title":"Joint Bone Spine"},{"key":"417_CR34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014;41:759\u201367.","journal-title":"J Rheumatol"},{"key":"417_CR35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Pu\u00e9chal","year":"2011","unstructured":"Pu\u00e9chal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still\u2019s disease. Arthritis Care Res (Hoboken). 2011;63:155\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"417_CR36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"AT Virtanen","year":"2019","unstructured":"Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019;33:15\u201332.","journal-title":"BioDrugs"},{"key":"417_CR37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/s10165-010-0348-9","volume":"21","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still\u2019s disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92\u20136.","journal-title":"Mod Rheumatol"},{"key":"417_CR38","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s10067-020-04949-0","volume":"39","author":"R Wang","year":"2020","unstructured":"Wang R, Li T, Ye S, Tan W, Zhao C, Li Y, et al. Macrophage activation syndrome associated with adult-onset Still\u2019s disease: a multicenter retrospective analysis. Clin Rheumatol. 2020;39:2379\u201386.","journal-title":"Clin Rheumatol"},{"issue":"Suppl 121","key":"417_CR39","first-page":"83","volume":"37","author":"XP Yang","year":"2019","unstructured":"Yang XP, Wang M, Li TF, Li W, Zhang L, Liu SY. Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2019;37(Suppl 121):83\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"417_CR40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.","journal-title":"J Hematol Oncol"},{"key":"417_CR41","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.2020005364","volume":"135","author":"AM Risitano","year":"2020","unstructured":"Risitano AM, de Latour RP. Ruxolitinib for steroid-resistant acute GVHD. Blood. 2020;135:1721\u20132.","journal-title":"Blood"},{"key":"417_CR42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","volume":"128","author":"S Maschalidi","year":"2016","unstructured":"Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint BG. Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128:60\u201371.","journal-title":"Blood"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00417-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00417-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:33:43Z","timestamp":1687782823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00417-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00417-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"12 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Science and Technology Project of Tianjin Health Commission (2020ZC20182).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"The study protocol was approved by the Ethical Committee of Tianjin Medical University General Hospital (IRB2022-WZ-034).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for their clinical and molecular data to be used for research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analysed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ZS and XL designed the study, analysed the data, and wrote and revised the report. RL, YW, and FH recruited patients, collected data, advised on interpreting data and revised the report. FH, XL, and WW advised on revising the report, writing \u2013 reviewing, and editing. All authors read, reviewed, and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}